Last reviewed · How we verify
NCT07029282: MOM-CARE
The MOM-CARE Trial : Evaluating Antenatal and Postnatal MMSPlus for Improved Infant Birth and Growth Outcomes
Phase 3 trial testing MMS in Newborn Health in 3,000 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Aga Khan University |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 3,000 |
| Start date | 8 July 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
Conditions studied
- Newborn Health — all drugs for Newborn Health →
- Multiple Micronutrient Deficiencies During Pregnancy — all drugs for Multiple Micronutrient Deficiencies During Pregnancy →
- Nutrition During Pregnancy — all drugs for Nutrition During Pregnancy →
- Adaptive Trial — all drugs for Adaptive Trial →
Sponsor
Aga Khan University
Who can join
Adults 15 to 49, female only, with Newborn Health or Multiple Micronutrient Deficiencies During Pregnancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial aims to learn if MMS Plus improves infant health compared to standard MMS during pregnancy and the postnatal period in women living in peri-urban areas of Karachi, Pakistan. It will also evaluate how MMS Plus affects infant growth during the first 6 months of life. The main questions it aims to answer are: 1. Does MMS Plus during pregnancy reduce the risk of poor infant outcomes compared to standard MMS, as measured on a 5-point ordinal scale ranging from perinatal mortality to term birth with appropriate, small, or large-for-gestational-age infants? 2. Does postnatal MMS Plus improve infant length velocity at 6 months of age among exclusively breastfed infants compared to standard MMS and iron/folic acid (IFA) supplementation? Researchers will compare: 1. MMS Plus versus standard MMS during pregnancy (antenatal phase) 2. MMS Plus versus standard MMS versus IFA after birth (postnatal phase) Participants will: 1. Be randomly assigned to receive either MMS Plus or standard MMS during pregnancy 2. Be re-randomized after delivery to receive either MMS Plus, standard MMS, or IFA supplements during the postnatal period 3. Receive supplements under double-blind conditions 4. Be followed through childbirth and until the infant is 6 months of age 5. Attend regular clinic visits for health monitoring, infant assessments, and data collection. This phase III adaptive randomized controlled trial will occur in three peri-urban catchment areas of Karachi, Pakistan.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07029282
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MMS
Trials testing the same drug.
- NCT06663228 — Rapid Histologic Assessment for Stereotactic Breast Biopsy: Enhancing Early Detection With Miniature Mass Spectrometry a · recruiting
Other Aga Khan University trials
Trials by the same sponsor.
- NCT07475793 — Image Guided Genicular Nerve Radiofrequency Ablation for Chronic Knee Osteoarthritis · NA · not yet recruiting
- NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg · NA · not yet recruiting
- NCT07356063 — Self-Efficacy Enhancement Using a Multicomponent Support Group for Caregivers of Children With DMD/SMA · NA · not yet recruiting
- NCT07451951 — Effectiveness of SQLNS vs MQLNS for Prevention of Undernutrition in Children 6-12 Months · NA · not yet recruiting
- NCT07357350 — Effectiveness of Pain Management Interventions in Patients With Abdominal and Pelvic Cancer · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07029282 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aga Khan University
- Last refreshed: 7 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07029282.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing